论文部分内容阅读
近日,来自法国巴黎第大学的科学家发现通过小分药物激活AMP依赖的蛋白酶(AMPK),能够特异性杀急性髓系白血病细胞(AML对于治疗该病的药物开发具重要意义。AMPK是细胞代谢的一主要调控因子,在不同细胞境下可表现出促癌和抑癌两不同的活性。在该项研究中研究人员发现AMPK特异激动剂GSK621能够选择性伤急性髓系白血病细胞,但会对正常的造血祖细胞产毒性。GSK621能够直接并异性激活AMPK,通过激活
Recently, scientists from the University of Paris, France, discovered that small-molecule drugs that activate AMP-dependent protease (AMPK) can specifically kill acute myeloid leukemia cells (AML for the development of drug treatment of the disease is of great significance.) AMPK is cell metabolism A major regulatory factor that exhibits two different activities of promoting cancer and suppressing cancer in different cell environments.In this study, we found that GSK621, an AMPK specific agonist, selectively injured acute myeloid leukemia cells, Of hematopoietic progenitor cells.GSK621 can directly and heterosexually activate AMPK through activation